Imatinib outcomes in chronic myeloid leukemia across diverse health care settings: a systematic review and meta-analysis

Blood Cancer Journal 2026 Open access

Read full text
Authors: Marisol Miranda-Galvis, Jon Wilson, Yazmin Reategui-Almonacid, Lily E. Johnston, Allison O. Taylor, Ramses Sadek, Kellen Tjioe, Jorge Cortes
DOI: 10.1038/s41408-026-01485-z
Cited by: 3
References: 13

Abstract

Targeting constitutive BCR::ABL1 kinase activity with tyrosine kinase inhibitors (TKIs), beginning with imatinib, has transformed CML management and substantially improved long-term survival [ 1 ]. Later-generation TKIs have further expanded frontline treatment options, enabling contemporaneous risk-adapted treatment strategies [ 2 ]. Nevertheless, despite sustained efficacy of imatinib in long-term follow-up of trials [ 3 ], treatment outcomes in routine practice remain heterogeneous, suggesting influences beyond disease biology and therapeutic effectiveness [ 4 ].

Fields of Study & Subjects

Chronic Myeloid Leukemia Treatments Myeloproliferative Neoplasms: Diagnosis and Treatment Chronic Lymphocytic Leukemia Research

Publication details

Journal / source
Blood Cancer Journal
Publisher
Springer Science and Business Media LLC
Volume
16
Issue
1
Publication date
23 March 2026
Language
EN